Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord mesenchymal stem cells (The Second Affiliated Hospital of Fujian Medical University)
- Development stage
- Unknown
- Lead developer
- The Second Affiliated Hospital of Fujian Medical University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Endoscopic Injection
01
Overview
Umbilical cord mesenchymal stem cells (UC-MSCs) is an investigational cell therapy being developed by The Second Affiliated Hospital of Fujian Medical University for the treatment of bronchopleural fistula (BF). BF is a severe complication that can occur after pulmonary resection, characterized by an abnormal passage between the bronchial tree and the pleural space. This therapy involves the local administration of mesenchymal stem cells derived from human umbilical cord tissue via endoscopic injection directly into the fistula site. UC-MSCs are utilized for their innate regenerative, immunomodulatory, and anti-inflammatory properties, which are hypothesized to promote tissue repair and facilitate the closure of the fistula. The approach is currently being evaluated in a Phase 1 clinical trial to assess its safety and preliminary efficacy.
- Other names
- UC-MSCshuman umbilical cord mesenchymal stem cells
Beyond the preview
Go deeper on umbilical cord mesenchymal stem cells (The Second Affiliated Hospital of Fujian Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord mesenchymal stem cells (The Second Affiliated Hospital of Fujian Medical University).